Trials / Completed
CompletedNCT01327911
Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)
A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Neurotech Pharmaceuticals · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.
Detailed description
Protocol for Extended Follow-up of a Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasia Type 2 (MacTel)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NT-501 implant | Ciliary neurotrophic factor (CNTF) implant |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2011-04-04
- Last updated
- 2016-11-22
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01327911. Inclusion in this directory is not an endorsement.